Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Thoracic Oncology

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e3181914111PMID 19096302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

  2008cited by this paper
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

  2007cited by this paper
• Risk factors differ for non‐small‐cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case‐control study in Japanese

  2007cited by this paper
• PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Uncommon V599E BRAF mutations in Japanese patients with lung cancer.

  2006cited by this paper
• Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

  2006cited by this paper
• Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  2005cited by this paper
• Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cited by this paper
• Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation

  2004cited by this paper
• CK20 expression, CDX2 expression, K‐ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR.

  2003cited by this paper
• Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.

  2001cited by this paper
• K-ras gene mutations in non-small cell lung cancer in Japanese.

  2000cited by this paper
• Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.

  2000cited by this paper
• K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

  1999cited by this paper
• K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.

  1990cited by this paper

• Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

  2026cites this paper
• Sex disparities in the association between rare earth elements exposure and genetic mutation frequencies in lung cancer patients

  2025cites this paper
• Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC

  2025cites this paper
• Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study.

  2025cites this paper
• Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples

  2025cites this paper
• TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.

  2025cites this paper
• Depicting growth characteristics with computed tomography for KRAS-mutated lung adenocarcinoma

  2025cites this paper
• The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes

  2024cites this paper
• The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions

  2024cites this paper
• EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass Opacities

  2024cites this paper
• Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization

  2024cites this paper
• Establishment and validation of a clinicopathological prediction model for postoperative recurrence of stage IA lung adenocarcinoma

  2024cites this paper
• Genetic Blueprints in Lung Cancer: Foundations for Targeted Therapies

  2024cites this paper
• Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study

  2024influential citation
• Computed tomography imaging and clinical characteristics of pulmonary ground‐glass nodules ≤2 cm with micropapillary pattern

  2023cites this paper
• Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

  2023cites this paper
• IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways

  2023cites this paper
• Identification of hypoxia‐related gene signatures based on multi‐omics analysis in lung adenocarcinoma

  2023cites this paper
• Enhancing tumour content and tumour cell count using microdissection contributes to higher detection rate of genetic mutations by next-generation sequencers

  2023cites this paper
• The GR-SGK1-NDRG1 Pathway as a Predictor of Recurrence and Prognosis in Lung Adenocarcinoma After Radical Surgery

  2023cites this paper
• CT-derived body composition associated with lung cancer recurrence after surgery.

  2023cites this paper
• Challenges in the Management of Lung Adenocarcinoma in Elderly Patients: Case Report

  2023cites this paper
• A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers

  2023cites this paper
• A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma

  2023cites this paper
• A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor.

  2023cites this paper
• Prognostic Effects Of Different Tp53 Mutations In Lung And Pancreatic Adenocarcinomas

  2022cites this paper
• Association of the KRAS genotype and clinicopathologic findings of resected non-small-cell lung cancer: A pooled analysis of 179 patients.

  2022cites this paper
• P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer

  2022cites this paper
• RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC

  2022cites this paper
• Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma.

  2022cites this paper
• Clinical significance of epidermal growth factor receptor mutations in resected stage IA non-small cell lung cancer

  2022cites this paper
• Biological Difference between L858R and Exon 19 Deletion Contributes to Recurrence-Free Survival of Resected Non-Small Cell Lung Cancer

  2022cites this paper
• A novel DNA damage repair-related signature for predicting prognositc and treatment response in non-small lung cancer

  2022cites this paper
• The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

  2022cites this paper
• Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification

  2022cites this paper
• Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.

  2022cites this paper
• Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report

  2022cites this paper
• Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

  2021cites this paper
• The Prognostic Value of Non-Predominant Micropapillary Pattern in a Large Cohort of Resected Invasive Lung Adenocarcinoma Measuring ≤3 cm

  2021cites this paper
• Novel genetic characteristics in low‐grade fetal adenocarcinoma of the lung

  2021cites this paper
• Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis

  2021influential citation
• Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer

  2021cites this paper
• The genomic landscape of young and old lung cancer patients highlights age‐dependent mutation frequencies and clinical actionability in young patients

  2021cites this paper
• Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer

  2021influential citation
• Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer

  2021cites this paper
• Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

  2021cites this paper
• Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects

  2021cites this paper
• Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component

  2021cites this paper
• Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.

  2021cites this paper
• Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation

  2021cites this paper
• Tumor evolutionary trajectories during the acquisition of invasiveness in early stage lung adenocarcinoma

  2020cites this paper
• Long-Term Recurrence of Completely Resected NSCLC

  2020cites this paper
• Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.

  2020cites this paper
• Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases.

  2020cites this paper
• Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma

  2020cites this paper
• Clinical signifi cance of molecular-genetic markers in the diagnosis and personalization of lung cancer therapy

  2020cites this paper
• Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis

  2020cites this paper
• A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment

  2020cites this paper
• Pleural invasion, epidermal growth factor receptor mutation and carcinoembryonic antigen level affect pleural lavage cytology-positive status in non-small-cell lung cancer.

  2020cites this paper
• Targeted RNA sequencing with touch imprint cytology samples for non‐small cell lung cancer patients

  2020cites this paper
• Lung Cancer Staging and Associated Genetic and Epigenetic Events

  2020cites this paper
• Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma

  2019cites this paper
• Prognostic and Predictive Value of Three DNA Methylation Signatures in Lung Adenocarcinoma

  2019cites this paper
• Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer

  2019cites this paper
• The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis

  2019cites this paper
• The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas

  2019cites this paper
• Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer.

  2019cites this paper
• The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery

  2019cites this paper
• Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.

  2019cites this paper
• Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer

  2019cites this paper
• Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.

  2018cites this paper
• Contribution of smoking habit to the prognosis of stage I KRAS-mutated non-small cell lung cancer

  2018cites this paper
• Increased risk of recurrence in resected EGFR‐positive pN0M0 invasive lung adenocarcinoma

  2018cites this paper
• Comprehensive review of fetal adenocarcinoma of the lung

  2018cites this paper
• Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis

  2018influential citation
• Prognosis of resected, early-stage, lung adenocarcinoma patients

  2018cites this paper
• Prognostic Biomarkers in Lung Cancer

  2018cites this paper
• Serous Effusions

  2018cites this paper
• Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)‐Mutated Non–Small‐Cell Lung Cancer (NSCLC)

  2018cites this paper
• Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

  2018cites this paper
• Ground glass opacities: Imaging, pathology, and gene mutations

  2018cites this paper
• The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.

  2018cites this paper
• Validation of the digital PCR system in tyrosine kinase inhibitor‐resistant EGFR mutant non‐small‐cell lung cancer

  2018cites this paper
• Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.

  2018cites this paper
• Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

  2018cites this paper
• The Prognostic Value of p 53 Expression and Ki-67 Proliferation Index in the Post Resection Lung Adenocarcinoma Cases

  2018cites this paper
• A multidimensional approach to understanding lung tumour aggressiveness

  2017cites this paper
• Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.

  2017cites this paper
• Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.

  2017cites this paper
• Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma

  2017cites this paper
• Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

  2017cites this paper
• Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K‐ras mutation

  2017cites this paper
• K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017cites this paper
• Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer.

  2017cites this paper
• Targeted Next-generation Sequencing of Circulating Biomarkers in Non-Small Cell Lung Cancer (NSCLC)

  2017cites this paper
• Molecular biomarkers for lung adenocarcinoma

  2017cites this paper
• Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma

  2017cites this paper
• Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma

  2017cites this paper
• Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci

  2017cites this paper